Bio-Techne (TECH) Corporate presentation summary

Company profile and business overview

• Headquartered in Minneapolis, MN, with about 3,000 employees and 34 global locations.

• FY2022 revenues reached $1.1B, with a market cap of $13B and NASDAQ listing under TECH.

• Product portfolio includes proteins, antibodies, proteomic and analytical instruments, spatial molecular biology, diagnostics, and consumables.

• Revenue by customer: 48% pharma/biotech, 22% academia, 15% OEM, 15% distributors; by geography: 59% Americas, 24% EMEA, 17% Asia.

Strategic growth and sustainability

• Five key strategies: core product innovation, geographic expansion, culture/talent growth, bolt-on M&A, and customer journey enhancement.

• Sustainability initiatives include ISO 14001 certification, energy/water/waste management, and Scope 1 & 2 GHG emissions reporting.

• Workforce diversity: 50% female globally, 52% female scientists, over 35% U.S. minorities; recognized by Forbes for diversity and as a top employer.

• Board features diverse membership and deep scientific expertise, led by an independent chair.

Financial performance and market positioning

• Achieved 22% actual organic growth and 17% organic growth adjusted for COVID in recent years.

• Cash from operations and adjusted operating income have shown consistent growth since 2013.

• Large addressable end markets estimated at $17B–$21B, with leading positions in proteomic research reagents, analytical tools, cell culture, spatial biology, liquid biopsy, molecular products, and diagnostic reagents.

• Targeting revenue growth from $1.1B in FY22 to ~$2B in FY26, driven by high-teens organic growth and portfolio expansion.